Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting

Journal of Clinical Oncology

Volumn 29, Issue 7, 2011, Pages 934-943

  Kulke, Matthew H ^a   Siu, Lillian L ^a   Tepper, Joel E ^a   Fisher, George ^a   Jaffe, Deborah ^a   Haller, Daniel G ^a   Ellis, Lee M ^a   Benedetti, Jacqueline K ^a   Bergsland, Emily K ^a   Hobday, Timothy J ^a   Van Cutsem, Eric ^a   Pingpank, James ^a   Oberg, Kjell ^a   Cohen, Steven J ^a   Posner, Mitchell C ^a   Yao, James C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; BEVACIZUMAB; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; OCTREOTIDE; PASIREOTIDE; PLACEBO; STREPTOZOCIN; SUNITINIB;

ARTIFICIAL EMBOLISM; CANCER STAGING; CARCINOID; CARCINOID SYNDROME; CONFERENCE PAPER; FUTUROLOGY; HEPATIC ARTERY EMBOLIZATION; HISTOPATHOLOGY; HUMAN; LIVER SURGERY; LIVER TRANSPLANTATION; NATIONAL HEALTH ORGANIZATION; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; TUMOR CLASSIFICATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; FORECASTING; HUMANS; MALE; NATIONAL CANCER INSTITUTE (U.S.); NEUROENDOCRINE TUMORS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 79952308016     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.2056     Document Type: Conference Paper

References (49)

1. Yao JC, Hassan M, Phan A, et al: One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063-3072, 2008
2. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97:934-959, 2003 (Pubitemid 36173145)
3. Rindi G, Klöppel G, Alhman H, et al: TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch 449:395-401, 2006 (Pubitemid 44451313)
4. Rindi G, Klöppel G, Couvelard A, et al: TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system. Virchows Arch 451:757-762, 2007 (Pubitemid 47497934)
5. Edge SB, Byrd DR, Compton CC, et al: AJCC Cancer Staging Manual (ed 7). New York, NY, Springer, 2010
6. Moran CA, Suster S, Coppola D, et al: Neuroendocrine carcinomas of the lung: A critical analysis. Am J Clin Pathol 131:206-221, 2009
7. Leotlela PD, Jauch A, Holtgreve-Grez H, et al: Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 10:437-450, 2003 (Pubitemid 38094880)
8. Kulke MH, Freed E, Chiang DY, et al: High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosomes Cancer 47:591-603, 2008 (Pubitemid 351748345)
9. Kim do H, Nagano Y, Choi IS, et al: Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes Chromosomes Cancer 47:84-92, 2008
10. Nagano Y, Kim do H, Zhang L, et al: Allelic alterations in pancreatic endocrine tumors identified by genome-wide single nucleotide polymorphism analysis. Endocr Relat Cancer 14:483-492, 2007 (Pubitemid 47242646)
11. Kvols LK, Moertel CG, O'Connell MJ, et al: Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analog. N Engl J Med 315:663-666, 1986 (Pubitemid 16055931)
12. O'Toole D, Ducreux M, Bommelaer G, et al: Treatment of carcinoid syndrome: A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 88:770-776, 2000 (Pubitemid 30091095)
13. Kvols L, Wiedenmann B, Oberg K, et al: Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study. J Clin Oncol 24:185s, 2006 (suppl; abstr 4082)
14. Beaumont JL, Liu Z, Choi S, et al: Relationship between neuroendocrine tumor-related symptoms and health-related quality of life. Presented at 2010 Gastrointestinal Cancers Symposium, Orlando, FL, January 22-24, 2010 (abstr 242)
15. Davies AH, Larsson G, Ardill J, et al: Development of a disease-specific quality of life questionnaire module for patients with gastrointestinal neuroendocrine tumours. Eur J Cancer 42:477-484, 2006 (Pubitemid 43227926)
16. Sarmiento JM, Que FG: Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 12:231-242, 2003 (Pubitemid 36210867)
17. Le Treut YP, Grégoire E, Belghiti J, et al: Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: An 85-case French multicentric report. Am J Transplant 8:1205-1213, 2008 (Pubitemid 351763685)
18. Gupta S, Johnson MM, Murthy R, et al: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: Variables affecting response rates and survival.Cancer 104:1590-1602, 2005
19. Kennedy AS, Dezarn WA, McNeillie P, et al: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: Early results in 148 patients. Am J Clin Oncol 31:271-279, 2008
20. King J, Quinn R, Glenn DM, et al: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113:921-929, 2008
21. Breeman WA, de Jong M, Kwekkeboom DJ, et al: Somatostatin receptor-mediated imaging and therapy: Basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 28:1421-1429, 2001
22. Teunissen JJ, Kwekkeboom DJ, de Jong M, et al: Endocrine tumours of the gastrointestinal tract: Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 19:595-616, 2005
23. Bushnell D: Treatment of metastatic carcinoid tumors with radiolabeled biologic molecules. J Natl Compr Canc Netw 7:760-764, 2009
24. Kwekkeboom DJ, de Herder WW, Kam BL, et al: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 26:2124-2130, 2008
25. Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28:1652-1659, 2010
26. Arnold R, Muller H, Schade-Brittinger C, et al: Placebo-controlled, double blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. Presented at 2009 Gastrointestinal Cancers Symposium, San Francisco, CA, January 15-17, 2009 (abstr 121)
27. Yao JC, Shah MH, Ito T, et al: A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET) (RADIANT-3). Ann Oncol 21:viii4, 2010
28. Raymond E, Niccoli-Sire P, Bang Y, et al: Updated results of the phase III trial of sunitinib versus placebo for treatment of advanced pancreatic neuroendocrine tumor (NET). Presented at 2010 Gastrointestinal Cancers Symposium, Orlando, FL, January 22-24, 2010 (abstr 127)
29. Kouvaraki MA, Ajani JA, Hoff P, et al: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762-4771, 2004
30. Moertel CG, Lefkopoulo M, Lipsitz S, et al: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519-523, 1992
31. Rinke A, Müller H, Schade-Brittinger C, et al: Placebo-controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 27:4656-4663, 2009
32. Pavel M, Hainsworth JD, Baudin E, et al: A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus + octreotide LAR vs. placebo + octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2). Ann Oncol 21:viii4, 2010 (abstr)
33. Sargent DJ, Hayes DF: Assessing the measure of a new drug: Is survival the only thing that matters? J Clin Oncol 26:1922-1923, 2008
34. Broglio KR, Berry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642-1649, 2009
35. Freidlin B, Korn EL, Hunsberger S, et al: Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol 25:2122-2126, 2007 (Pubitemid 46972800)
36. Dodd LE, Korn EL, Freidlin B, et al: Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense? J Clin Oncol 26:3791-3796, 2008
37. Dromain C, de Baere T, Baudin E, et al: MR imaging of hepatic metastases caused by neuroendocrine tumors: Comparing four techniques. AJR Am J Roentgenol 180:121-128, 2003 (Pubitemid 36008698)
38. Debray MP, Geoffroy O, Laissy JP, et al: Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol 74:1065-1070, 2001 (Pubitemid 33121143)
39. Eriksson B, Oberg K, Stridsberg M: Tumor markers in neuroendocrine tumors. Digestion 62:33-38, 2000 (suppl 1) (Pubitemid 30665937)
40. Janson ET, Holmberg L, Stridsberg M, et al: Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8:685-690, 1997 (Pubitemid 27372168)
41. Yao JC, Lombard-Bohas C, Baudin E, et al: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol 28:69-76, 2010
42. Gerson SL: Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20:2388-2399, 2002
43. Kulke MH, Hornick JL, Frauenhoffer C, et al: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15:338-345, 2009
44. Yao JC, Phan A, Hoff PM, et al: Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26:1316-1323, 2008
45. Yao JC, Phan AT, Fogleman D, et al: Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol 28:301s, 2010 (suppl; abstr 4002)
46. Yao JC, Phan AT, Chang DZ, et al: Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol 26:4311-4318, 2008
47. Hobday TJ, Rubin J, Holen K, et al: MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study (abstract). J Clin Oncol 25:199s, 2007 (suppl; abstr 4504)
48. Kulke MH, Lenz HJ, Meropol NJ, et al: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403-3410, 2008
49. Phan AT, Yao JC, Fogelman DR, et al: A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (Sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 28:301s, 2010 (suppl; abstr 4001)